| Title |
Stem cell delivery of therapies for brain disorders
|
|---|---|
| Published in |
Clinical and Translational Medicine, July 2014
|
| DOI | 10.1186/2001-1326-3-24 |
| Pubmed ID | |
| Authors |
Alexander Aleynik, Kevin M Gernavage, Yasmine SH Mourad, Lauren S Sherman, Katherine Liu, Yuriy A Gubenko, Pranela Rameshwar |
| Abstract |
The blood brain barrier (BBB) poses a problem to deliver drugs for brain malignancies and neurodegenerative disorders. Stem cells such as neural stem cells (NSCs) and mesenchymal stem cells (MSCs) can be used to delivery drugs or RNA to the brain. This use of methods to bypass the hurdles of delivering drugs across the BBB is particularly important for diseases with poor prognosis such as glioblastoma multiforme (GBM). Stem cell treatment to deliver drugs to neural tumors is currently in clinical trial. This method, albeit in the early phase, could be an advantage because stem cells can cross the BBB into the brain. MSCs are particularly interesting because to date, the experimental and clinical evidence showed 'no alarm signal' with regards to safety. Additionally, MSCs do not form tumors as other more primitive stem cells such as embryonic stem cells. More importantly, MSCs showed pathotropism by migrating to sites of tissue insult. Due to the ability of MSCs to be transplanted across allogeneic barrier, drug-engineered MSCs can be available as off-the-shelf cells for rapid transplantation. This review discusses the advantages and disadvantages of stem cells to deliver prodrugs, genes and RNA to treat neural disorders. |
X Demographics
The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 25% |
| Netherlands | 1 | 13% |
| Venezuela, Bolivarian Republic of | 1 | 13% |
| United Kingdom | 1 | 13% |
| Unknown | 3 | 38% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 6 | 75% |
| Scientists | 1 | 13% |
| Practitioners (doctors, other healthcare professionals) | 1 | 13% |
Mendeley readers
The data shown below were compiled from readership statistics for 156 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Iran, Islamic Republic of | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 154 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 27 | 17% |
| Student > Master | 22 | 14% |
| Student > Bachelor | 22 | 14% |
| Researcher | 18 | 12% |
| Student > Postgraduate | 8 | 5% |
| Other | 16 | 10% |
| Unknown | 43 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 26 | 17% |
| Medicine and Dentistry | 26 | 17% |
| Biochemistry, Genetics and Molecular Biology | 16 | 10% |
| Neuroscience | 12 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 5% |
| Other | 22 | 14% |
| Unknown | 46 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 July 2021.
All research outputs
#6,572,065
of 25,374,647 outputs
Outputs from Clinical and Translational Medicine
#255
of 1,060 outputs
Outputs of similar age
#57,682
of 240,076 outputs
Outputs of similar age from Clinical and Translational Medicine
#4
of 9 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 1,060 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.2. This one has done well, scoring higher than 75% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 240,076 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one. This one has scored higher than 5 of them.